Published in Nat Rev Clin Oncol on March 22, 2011
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology. PLoS One (2015) 2.02
MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 1.45
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys (2012) 1.43
New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med (2013) 1.35
Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist (2012) 1.25
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol (2014) 1.14
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One (2012) 1.11
The biology and treatment of oligometastatic cancer. Oncotarget (2015) 1.08
Radical irradiation of extracranial oligometastases. J Clin Oncol (2014) 1.07
Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol (2013) 1.05
14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget (2015) 1.02
Extending the Frontiers Beyond Thermal Ablation by Radiofrequency Ablation: SBRT, Brachytherapy, SIRT (Radioembolization). Viszeralmedizin (2014) 0.98
Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging (2016) 0.97
Radiation oncology in the era of precision medicine. Nat Rev Cancer (2016) 0.97
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis (2014) 0.96
Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. Ann Surg (2016) 0.96
Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax (2014) 0.95
Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol (2012) 0.94
Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res (2013) 0.93
Stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol (2014) 0.92
Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel) (2014) 0.91
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91
Liver metastases and SBRT: A new paradigm? Rep Pract Oncol Radiother (2014) 0.91
Near infrared photoimmunotherapy for lung metastases. Cancer Lett (2015) 0.88
Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer. World J Gastroenterol (2014) 0.87
Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol (2014) 0.87
Prognostic value of expression of molecular markers in adenoid cystic cancer of the salivary glands compared with lymph node metastasis: a retrospective study. World J Surg Oncol (2012) 0.86
Pulmonary metastasectomy in colorectal cancer: a prospective study of demography and clinical characteristics of 543 patients in the Spanish colorectal metastasectomy registry (GECMP-CCR). BMJ Open (2013) 0.86
Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer. Breast Care (Basel) (2011) 0.85
Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol (2012) 0.84
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer (2014) 0.83
Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model. Oncotarget (2015) 0.83
A filter-flow perspective of haematogenous metastasis offers a non-genetic paradigm for personalised cancer therapy. Eur J Cancer (2014) 0.83
Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. World J Urol (2015) 0.83
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res (2014) 0.82
Oligometastases: the new paradigm and options for radiotherapy. A critical review. Strahlenther Onkol (2013) 0.82
CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer : A prospective evaluation of 95 patients/118 lesions. Strahlenther Onkol (2013) 0.82
Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases. Jpn J Clin Oncol (2016) 0.80
Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer. Radiat Oncol (2012) 0.80
Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J Thorac Dis (2015) 0.80
Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer. Front Oncol (2013) 0.80
SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. Front Oncol (2015) 0.80
Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One (2014) 0.79
Contemporary treatment with radiosurgery for spine metastasis and spinal cord compression in 2015. Radiat Oncol J (2015) 0.79
Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB (Oxford) (2015) 0.79
Oligometastasis and oligo-recurrence: more than a mirage. Radiat Oncol (2014) 0.79
Osseous oligometastases from thymic carcinoma: a case report suggesting the effectiveness of palliative-intent radiotherapy treatment. Onco Targets Ther (2016) 0.78
Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother (2014) 0.78
Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer. BMC Cancer (2016) 0.78
Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med (2012) 0.78
Resection of Large Metachronous Liver Metastasis with Gastric Origin: Case Report and Review of the Literature. Cureus (2016) 0.78
In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases. Mol Ther (2017) 0.77
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77
Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study. Medicine (Baltimore) (2016) 0.77
Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib. Oncotarget (2016) 0.77
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer. BMC Cancer (2016) 0.77
Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clin Mol Hepatol (2016) 0.76
Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys (2016) 0.75
Oligometastatic Prostate Cancer. Curr Treat Options Oncol (2016) 0.75
Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer (2015) 0.75
Liver resection for HER2-enriched breast cancer metastasis: case report and review of the literature. Surg Case Rep (2017) 0.75
Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors. Radiat Oncol (2014) 0.75
Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. Ann Surg Oncol (2015) 0.75
Predictors for long-term survival free from whole brain radiation therapy in patients treated with radiosurgery for limited brain metastases. Front Oncol (2015) 0.75
Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. J Thorac Dis (2017) 0.75
History and present status of pulmonary metastasectomy in colorectal cancer. World J Gastroenterol (2014) 0.75
An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology. Cancer Nanotechnol (2017) 0.75
Synchronous Oligometastatic Non-Small Cell Lung Cancer and Isolated Renal Cell Carcinoma: A Case Report and Literature Review. Cureus (2015) 0.75
How aggressive one need to be in treatment of patients with oligometastasis from non-small cell lung cancer? J Thorac Dis (2017) 0.75
How to Create Evidence for the Integration of Local and Locoregional Treatments in Future Oncological Treatment Concepts? Viszeralmedizin (2014) 0.75
Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases. Exp Ther Med (2014) 0.75
Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy (2016) 0.75
Computed tomography-guided implantation of (125)I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results. J Contemp Brachytherapy (2017) 0.75
Surveillance of anal carcinoma after radiochemotherapy : A retrospective analysis of 80 patients. Strahlenther Onkol (2017) 0.75
Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed? Visc Med (2017) 0.75
Metastatic bone disease from breast cancer: a review of minimally invasive techniques for diagnosis and treatment. Eur J Orthop Surg Traumatol (2017) 0.75
Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis (2017) 0.75
Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Int J Radiat Oncol Biol Phys (2017) 0.75
Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother (2015) 0.75
Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol (2016) 0.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res (2008) 1.68
Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol (2013) 1.48
MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 1.45
Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys (2005) 1.39
Early prostate cancer: clinical decision-making. Lancet (2003) 1.37
Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res (2009) 1.28
The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer (2004) 1.14
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One (2012) 1.11
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol (2004) 1.09
Receiver operating characteristic analysis: a general tool for DNA array data filtration and performance estimation. Genomics (2003) 1.08
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis (2014) 0.96
Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol (2002) 0.95
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest (2002) 0.85
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther (2004) 0.81
Early prostate cancer: hedonic prices model of provider-patient interactions and decisions. Int J Radiat Oncol Biol Phys (2007) 0.77
Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. Cancer (2003) 0.77
Premise, promise, paradigm and prophesy. Nat Clin Pract Oncol (2005) 0.76
Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer (2003) 0.76
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 0.75
Letrozole in breast cancer. N Engl J Med (2004) 0.75
Debunking dogma and developing theses. Eur J Cancer (2005) 0.75
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat (2003) 0.75
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Res Treat (2003) 0.75
An evidence-based analysis of the management of localized prostate cancer. Cancer J (2002) 0.75
Unintended consequences. Nat Clin Pract Oncol (2007) 0.75